Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 11/20 | 0.38 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 0.38 |
| ▸ | HTR2B | P41595 | 14/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12433759 | 0.92 | HTR2B (0.44) | HTR2BHTR2CHTR2AALDH1A1L3MBTL1 | |
| Succinic Acid SCHEMBL2206275 | 0.90 | ALDH1A1 (0.45) | HTR2BHTR2CHTR2AALDH1A1L3MBTL1 | |
| Succinic Acid SCHEMBL2207859 | 0.85 | ALDH1A1 (0.40) | HTR2BHTR2CHTR2AALDH1A1L3MBTL1 | |
| Succinic Acid SCHEMBL2208520 | 0.81 | L3MBTL1 (0.45) | HTR2BHTR2CHTR2AALDH1A1L3MBTL1 | |
| Succinic Acid SCHEMBL2210128 | 0.81 | HTR2B (0.39) | HTR2BHTR2CHTR2AALDH1A1MEN1 | |
| Succinic Acid SCHEMBL2210659 | 0.81 | HTR2B (0.42) | HTR2BHTR2CHTR2AMEN1KMT2A | |
| Succinic Acid SCHEMBL2215481 | 0.80 | HTR2B (0.46) | HTR2BHTR2CHTR2A | |
| SCHEMBL2208510 | 0.79 | HTR2A (0.48) | HTR2BHTR2CHTR2AALDH1A1L3MBTL1 | |
| Succinic Acid SCHEMBL2208827 | 0.78 | HTR2C (0.42) | HTR2BHTR2CHTR2A | |
| Succinic Acid SCHEMBL2205533 | 0.77 | HTR2B (0.39) | HTR2BHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924578-B1 | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| US-7981882-B2 | e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3B, HTR1A | HTR2C 1/4885HTR2A 5/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.